Abstract
Hepatocellular carcinoma (HCC) and colorectal carcinoma with hepatic metastases (mCRC) are cancers with poor prognosis and limited therapeutic options. New approaches are needed and adoptive immunotherapy with Vγ9Vδ2 T lymphocytes represents an attractive strategy. Indeed, Vγ9Vδ2 T cells were shown to exhibit efficient lytic activity against various human tumor cell lines, and in vitro Vγ9Vδ2 T expansion protocol based on single phosphoantigen stimulation could be easily performed for healthy donors. However, a low proliferative response of Vγ9Vδ2 T cells was observed in about half of the cancer patients, leading to an important limitation in the development of Vγ9Vδ2 T cell-based immunotherapy. Here, for the first time in the context of cancer patients, Vγ9Vδ2 T cell expansions were performed by co-culturing peripheral blood mononuclear cell (PBMCs) with autologous dendritic cells (DCs) pretreated with aminobisphosphonate zoledronate. For patients not responding to the conventional culture protocol, co-culture of PBMC with zoledronate-pretreated DCs induced strong cell expansion and allowed reaching a minimal rate of purity of 70% of Vγ9Vδ2 T cells. The potent immunostimulatory activity of zoledronate-treated DCs was associated with higher amount of isopentenyl pyrophosphate (IPP) in the culture and was correlated with better ability to activate Vγ9Vδ2 T cells as measured by IFN-γ production. Moreover, we demonstrated that the cytotoxic level of Vγ9Vδ2 T cells against freshly autologous tumor cells isolated from patients could be significantly increased by pretreating the tumor cells with zoledronate. Thus, this method of generating Vγ9Vδ2 T cells leads eligible for Vγ9Vδ2 T cell adoptive immunotherapy the HCC and mCRC patients.
Similar content being viewed by others
Abbreviations
- HCC:
-
Hepatocellular carcinoma
- mCRC:
-
Colorectal cancer with hepatic metastases
- IPP:
-
Isopentenyl pyrophosphate
- ABP:
-
Aminobisphosphonate
- BrHPP:
-
Bromohydrin pyrophosphate
- PBMC:
-
Peripheral blood mononuclear cell
- DC:
-
Dendritic cell
- mAb:
-
Monoclonal antibody
- GM-CSF:
-
Granulocyte-macrophage colony-stimulating factor
- cpm:
-
Count per minute
- P-Ag:
-
Phosphoantigen
References
Dupont-Bierre E, Compagnon P, Raoul JL, Fayet G, de Lajarte-Thirouard AS, Boudjema K (2005) Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg 201(5):663–670. doi:10.1016/j.jamcollsurg.2005.06.265
Thomas MB, O’Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P (2008) Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 15(4):1008–1014. doi:10.1245/s10434-007-9705-0
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299–308. doi:10.1038/nrc2355
Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67(1):5–8. doi:10.1158/0008-5472.CAN-06-3069
Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, Bonneville M, Jotereau F (2005) V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol 175(8):5481–5488
Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, Caignard A (2005) Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 174(3):1338–1347
Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pintiere C, Daniel P, Genetet N, Meunier B, Dupont-Bierre E, Boudjema K, Catros V (2008) Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother 57(4):531–539. doi:10.1007/s00262-007-0391-3
Thomas ML, Samant UC, Deshpande RK, Chiplunkar SV (2000) Gammadelta T cells lyse autologous and allogenic oesophageal tumours: involvement of heat-shock proteins in the tumour cell lysis. Cancer Immunol Immunother 48(11):653–659
Kenna T, Golden-Mason L, Norris S, Hegarty JE, O’Farrelly C, Doherty DG (2004) Distinct subpopulations of gamma delta T cells are present in normal and tumor-bearing human liver. Clin Immunol 113(1):56–63. doi:10.1016/j.clim.2004.05.003
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232):802–807. doi:10.1016/S0140-6736(00)02654-4
Bonneville M, Scotet E (2006) Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18(5):539–546
Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G (2003) Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197(2):163–168
Berenson JR (2005) Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10(1):52–62. doi:10.1634/theoncologist.10-1-52
Stresing V, Daubine F, Benzaid I, Monkkonen H, Clezardin P (2007) Bisphosphonates in cancer therapy. Cancer Lett 257(1):16–35. doi:10.1016/j.canlet.2007.07.007
Wada A, Fukui K, Sawai Y, Imanaka K, Kiso S, Tamura S, Shimomura I, Hayashi N (2006) Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma. J Hepatol 44(1):142–150. doi:10.1016/j.jhep.2005.09.022
Winter MC, Coleman RE (2009) Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr Opin Oncol 21(6):499–506. doi:10.1097/CCO.0b013e328331c794
Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Negrier S (2008) Phase-I study of innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57(11):1599–1609. doi:10.1007/s00262-008-0491-8
Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H (2007) Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56(4):469–476
Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1):200–206
Eberl M, Jomaa H, Hayday AC (2004) Integrated immune responses to infection—cross-talk between human gammadelta T cells and dendritic cells. Immunology 112(3):364–368. doi:10.1111/j.1365-2567.2004.01921.x
Munz C, Steinman RM, Fujii S (2005) Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 202(2):203–207. doi:10.1084/jem.20050810
Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B, Pantaleoni F, Foglietta M, Boccadoro M, Massaia M (2007) Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 110(3):921–927. doi:10.1182/blood-2006-09-044321
Jauhiainen M, Monkkonen H, Raikkonen J, Monkkonen J, Auriola S (2009) Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography–electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877(27):2967–2975. doi:10.1016/j.jchromb.2009.07.010
Jiang J, Nilsson-Ehle P, Xu N (2006) Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 5:4. doi:10.1186/1476-511X-5-4
Fernandez A, Colell A, Garcia-Ruiz C, Fernandez-Checa JC (2008) Cholesterol and sphingolipids in alcohol-induced liver injury. J Gastroenterol Hepatol 23(Suppl 1):S9–S15. doi:10.1111/j.1440-1746.2007.05280.x
Devilder MC, Maillet S, Bouyge-Moreau I, Donnadieu E, Bonneville M, Scotet E (2006) Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J Immunol 176(3):1386–1393
Barkholt L, Danielsson R, Calissendorff B, Svensson L, Malihi R, Remberger M, Uzunel M, Thorne A, Ringden O (2004) Indium-111-labelled donor-lymphocyte infusion by way of hepatic artery and radio-frequency ablation against liver metastases of renal and colon carcinoma after allogeneic hematopoietic stem-cell transplantation. Transplantation 78(5):697–703
Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346–2357
Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, Yamazaki S, Hasegawa H, Suzuki K, Yamagata M et al (1991) Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report. Cancer 68(11):2391–2396
Poccia F, Boullier S, Lecoeur H, Cochet M, Poquet Y, Colizzi V, Fournie JJ, Gougeon ML (1996) Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol 157(1):449–461
Acknowledgments
The authors thank C. Guillouzo (INSERM U522, Rennes) for providing HCC cell lines and expert assistance in the culture of normal hepatocytes, L. Jégu (Département de Chirurgie Hépatobiliaire et Digestive, CHU de Rennes) for assistance in patient inclusion and Innate Pharma (Marseille) for providing bromohydrin pyrophosphate (BrHPP, Phosphostim™). This study was supported by funds from the Comité Grand Ouest de la Ligue contre le Cancer and the Institut National du Cancer (PL075).
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
F. Cabillic and O. Toutirais contributed equally to this work.
Rights and permissions
About this article
Cite this article
Cabillic, F., Toutirais, O., Lavoué, V. et al. Aminobisphosphonate-pretreated dendritic cells trigger successful Vγ9Vδ2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother 59, 1611–1619 (2010). https://doi.org/10.1007/s00262-010-0887-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-010-0887-0